PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Pioglitazone

Drugs in development · updated 30 October 2026

Pioglitazone: clinical trials and development status

Other names and codes: Actos

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 11 October 2000

As of 30 October 2026 Pioglitazone is in 22 active clinical trials (recruiting or ongoing, phases I–III) for 22 diseases. The most advanced phase is III.

22Active trials
IIIMost advanced phase
22Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Pioglitazone and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Type 2 diabetesIII4NCT06246799
Anti-neutrophil cytoplasmic antibody-associated vasculitisIII1NCT05946564
VasculitisIII1NCT05946564
Breast neoplasmII3NCT07117630
DiabetesII3NCT06729996
Aortic valve calcificationII1NCT05875675
Aortic valve stenosisII1NCT05875675
Chronic pancreatitisII1NCT06729996
Chronic phase chronic myelogenous leukemiaI–II1NCT02767063
Chronic progressive multiple sclerosisI–II1NCT03109288
Cognitive dysfunctionII1NCT06594172
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveII1NCT02889003
Lung neoplasmII1NCT05919147
Multiple sclerosisI–II1NCT03109288
Non-alcoholic Fatty Liver DiseaseII1NCT04501406
PancreatitisII1NCT06729996
Pulmonary hypertensionII1NCT06336798
Cardiovascular diseaseI1NCT06446531
Castration-resistant prostatic neoplasmI1NCT02592317
Human body weightI1NCT06446531
HyperinsulinismEarly I1NCT05753657
ObesityEarly I1NCT03866408

Everything on Pioglitazone

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch